Detection of autoantibodies to survivin in cervical mucus from patients with human papillomavirus-associated cervical cancer and precursor lesions

References

• Abu-Shakra M, Buskila D, Ehrenfeld M, Conrad K, Shoenfeld Y. Cancer and autoimmunity: Autoimmune and rheumatic features in patients with malignancies. Ann Rheum Dis 2001; 60: 433–440
   PubMed Web of Science ®Google Scholar
• Soussi T. p53 antibodies in the sera of patients with various types of cancer. A review. Cancer Res 2000; 60: 1777–1788
   PubMed Web of Science ®Google Scholar
• Zhang J-Y, Casiano CA, Peng X-X, Koziol JA, Chan EKL, Tan EM. Enhancement of antibody detection in cancer using panel of recombinant tumo-associated antigens. Cancer Epidemiol Biomarkers Prev 2003; 12: 136–143
   PubMed Web of Science ®Google Scholar
• Himoto T, Kuriyama S, Zhang J-Y, Chan EKL, Kimura Y, Masaki T, Uchida N, Nishioka M, Tan EM. Analyses of autoantibodies against tumor-associated antigens in patients with hepatocellular carcinoma. Int J Oncol 2005; 27: 1079–1085
   Google Scholar
• Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997; 3: 917–921
   PubMed Web of Science ®Google Scholar
• Yang D, Welm A, Bishop JM. Cell division and cell survival in the absence of survivin. Proc Natl Acad Sci USA 2004; 101: 15100–15105
   PubMedGoogle Scholar
• Kawasaki H, Altieri DC, Lu CD, Toyoda M, Tenjo T, Tanigawa N. Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res 1998; 58: 5071–5074
   PubMed Web of Science ®Google Scholar
• LaCasse EC, Baird S, Korneluk RG, MacKenzie AE. The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene 1998; 17: 3247–3259
   PubMed Web of Science ®Google Scholar
• Lu CD, Altieri DC, Tanigawa N. Expression of a novel antiapoptosis gene, survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas. Cancer Res 1998; 58: 1808–1812
   PubMed Web of Science ®Google Scholar
• Schmidt SM, Schag K, Muller MR, Weck MM, Appel S, Kanz L, Grunebach F, Brossart P. Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells. Blood 2003; 102: 571–576
   PubMed Web of Science ®Google Scholar
• Andersen MH, Pedersen LO, Becker JC, Straten PT. Identification of a cytotoxic T lymphocyte response to the apoptosis inhibitor protein survivin in cancer patients. Cancer Res 2001; 61: 869–872
   PubMed Web of Science ®Google Scholar
• Casati C, Dalerba P, Rivoltini L, Gallino G, Deho P, Rini F, Belli F, Mezzanzanica D, Costa A, Andreola S, Leo E, Parmiani G, Castelli C. The apoptosis inhibitor protein survivin induces tumor-specific CD8+ and CD4+ T cells in colorectal cancer patients. Cancer Res 2003; 63: 4507–4515
   PubMed Web of Science ®Google Scholar
• Rohayem J, Diestelkoetter P, Weigle B, Oehmichen A, Schmitz M, Mehlhorn J, Conrad K, Rieber EP. Antibody response to the tumor-associated inhibitor of apoptosis protein survivin in cancer patients. Cancer Res 2000; 60: 1815–1817
   PubMed Web of Science ®Google Scholar
• Yagihashi A, Asanuma K, Nakamura M, Araya J, Mano Y, Torigoe T, Kobayashi D, Watanabe N. Detection of anti-survivin antibody in gastrointestinal cancer patients. Clin Chem 2001; 47: 1729–1731
   PubMed Web of Science ®Google Scholar
• Chang JT, Wong F-W, Liao C-T, Chen I-H, Wang H-M, Cheng A-J. Enzyme immunoassay for serum autoantibody to survivin and its findings in head-and-neck cancer patients. Clin Chem 2004; 50: 1261–1264
   PubMedGoogle Scholar
• Yagihashi A, Ohmura T, Asanuma K, Kobayashi D, Tsuji N, Torigoe T, Sato N, Hirata K, Watanabe N. Detection of autoantibodies to survivin and livin in sera from patients with breast cancer. Clin Chim Acta 2005; 362: 125–130
   PubMed Web of Science ®Google Scholar
• Megliorino R, Shi FD, Peng XX, Wang X, Chan EK, Tan EM, Zhang JY. Autoimmune response to anti-apoptotic protein survivin and its association with antibodies to p53 and c-myc in cancer detection. Cancer Detect Prev 2005; 29: 241–248
   PubMedGoogle Scholar
• Walboomers JMM, Jacobs MV, Manos MM. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189: 12–19
   PubMed Web of Science ®Google Scholar
• Frost M, Jarboe EA, Orlicky D, Gianani R, Thompson LC, Enomoto T, Shroyer KR. Immunohistochemical localization of survivin in benign cervical mucosa, cervical dysplasia, and invasive squamous cell carcinoma. Am J Clin Pathol 2002; 117: 738–744
   PubMed Web of Science ®Google Scholar
• Solomon D. The 1988 Bethesda system for reporting cervical/vaginal cytological diagnosis. JAMA 1989; 262: 931–934
   PubMedGoogle Scholar
• Kaye JN, Cason J, Pakarian JB, Jewers RJ, Kell B, Bible J, Raju KS, Best JM. Viral load as a determinant for transmission of human papillomavirus type 16 from mother to child. J Med Virol 1994; 44: 415–421
   PubMed Web of Science ®Google Scholar
• Manos MM, Ting Y, Wright DK, Lewis AJ, Broker TR, Wolinsky SM. Use of polymerase chain reaction amplification for the detection of genital human papillomaviruses. Cancer Cell 1989; 7: 209–214
   Google Scholar
• Saiki RA, Bugawan TL, Horn GT, Mullis KB, Erlich HA. Analysis of enzymatically amplified β-globin and HLA DQ alpha DNA with allele specific oligonucleotide probes. Nature 1986; 324: 163–166
   PubMed Web of Science ®Google Scholar
• Yagihashi A, Asanuma K, Kobayashi D, Tsuji N, Torigoe T, Sato N, Watanabe N. Autoantibodies to survivin in patients with chronic hepatitis and hepatocellular carcinoma. Autoimmunity 2005; 38: 445–448
   PubMed Web of Science ®Google Scholar
• Singh A, Sharma H, Salhan S, Gupta SD, Bhatla N, Jain SK, Singh N. Evaluation of expression of apoptosis-related proteins and their correlation with HPV, telomerase activity, and apoptotic index in cervical cancer. Pathobiology 2004; 71: 314–322
   PubMed Web of Science ®Google Scholar
• Rocha-Zavaleta L, Pereira-Suarez AL, Yescas G, Cruz-Mimiaga RM, Garcia-Carranca A, Cruz-Talonia F. Mucosal IgG and IgA responses to human papillomavirus type 16 capsid proteins in HPV16-infected women without visible pathology. Viral Immunol 2003; 16: 159–168
   PubMed Web of Science ®Google Scholar
• Bierl C, Karem K, Poon AC, Swan D, Tortolero-Luna G, Follen M, Wideroff L, Unger ER, Reeves WC. Correlates of cervical mucosal antibodies to human papillomavirus 16: Results from a case control study. Gynecol Oncol 2005; 99: S262–S268
   PubMed Web of Science ®Google Scholar
• Branca M, Giorgi C, Santini D, Di Bonito L, Ciotti M, Benedetto A, Casolati EA, Favalli C, Paba P, Di Bonito P, Mariani L, Syrjanen S, Bonifacio D, Accardi L, Zanconati F, Syrjanen K. HPV-pathogen ISS study group. Survivin as a marker of cervical intraepithelial neoplasia and high-risk human papillomavirus and a predictor of virus clearance and prognosis in cervical cancer. Am J Clin Pathol 2005; 124: 113–121
   PubMedGoogle Scholar
• Lok AS. Hepatitis B infection: Pathogenesis and management. J Hepatol 2000; 32: 89–97
   PubMed Web of Science ®Google Scholar
• Hirohashi Y, Torigoe T, Maeda A, Nabeta Y, Kamiguchi K, Sato T, Yoda J, Ikeda H, Hirata K, Yamanaka N, Sato N. An HLA-A24-restricted cytotoxic T lymphocyte epitope of a tumor-associated protein, survivin. Clin Cancer Res 2002; 8: 1731–1739
   PubMed Web of Science ®Google Scholar
• Rever S, Becker JC, Svane IM, Ralfkiaer E, Straten PT, Andersen MH. HLA-B35-restricted immune response against survivin in cancer patients. Int J Cancer 2004; 108: 937–941
   Google Scholar